Entrada Therapeutics, Inc. — Director's Dealing 2021

Oct 29, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Entrada Therapeutics, Inc. (TRDA)
CIK: 0001689375
Period of Report: 2021-10-28

Reporting Person: Redmile Group, LLC (10% Owner)
Reporting Person: Green Jeremy (10% Owner)
Reporting Person: Redmile Biopharma Investments III, L.P. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series B Convertible Preferred Stock	$		Common Stock (954420)		Indirect

Footnotes

F1: The Series B convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the holder's election, or automatically upon the closing of the Issuer's initial public offering, for no consideration and has no expiration date. This Form 3 reflects that, on October 22, 2021, the Issuer effected a one-for-7.235890014 reverse stock split of its common stock, as a result of which the conversion ratio of the Series B convertible preferred stock was proportionately adjusted.

F2: These securities are directly owned by Redmile Biopharma Investments III, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.